Related Experiment Video
Updated: Aug 6, 2026
Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
Published on: April 21, 2012
A Retrospective Study of the Management of Pediatric Cutaneous Leishmaniasis in a Non-endemic Setting
Owain Donnelly1,2, Hagop Krikorian3, Jonathan Cohen3
1From the Hospital for Tropical Diseases, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Insights
Treatments like miltefosine, meglumine antimoniate, and liposomal amphotericin B (LAMB) are effective for childhood cutaneous leishmaniasis (CL) in non-endemic areas. These therapies demonstrate good tolerability and safety profiles in pediatric patients.
Area of Science:
- Tropical medicine
- Pediatric infectious diseases
- Dermatology
Background:
- Cutaneous leishmaniasis (CL) is a neglected tropical disease caused by Leishmania parasites.
- Limited evidence exists for managing CL in children and adolescents, especially in non-endemic regions.
- This study reports on 17 pediatric CL cases treated in a UK specialist center.
Purpose of the Study:
- To analyze treatment outcomes for children and adolescents with CL in a non-endemic setting.
- To evaluate the safety and efficacy of different therapeutic regimens.
- To inform clinical management strategies for pediatric CL.
Main Methods:
- Retrospective analysis of 17 patients under 18 with CL treated between 2015 and 2025.
- Data collected included demographics, Leishmania species, treatments administered, and outcomes.
- Causative species identified: L. donovani complex, L. major, L. tropica, and L. Viannia subgenus.
Main Results:
- First-line treatments included oral miltefosine (9/17), intralesional meglumine antimoniate (3/17), and intravenous liposomal amphotericin B (LAMB; 3/17).
- Complete resolution occurred in 14 of 15 patients within 180 days; one lesion took longer to heal.
- Adverse effects were mild/moderate in 35% (6/17) of patients.
Conclusions:
- Miltefosine, intralesional meglumine antimoniate, and LAMB are effective and well-tolerated treatments for pediatric CL in non-endemic settings.
- Managing pediatric CL presents unique challenges, including biopsy difficulties and dosing uncertainties.
- Individualized, multidisciplinary care involving patients and families is recommended.
Introduction:
Cutaneous leishmaniasis (CL), caused by protozoa of the genus Leishmania , is a neglected tropical disease. Limited evidence exists to inform the management of CL in children and adolescents, and experience in non-endemic settings varies significantly. We report case data and treatment outcomes for 17 children and young people diagnosed with CL and treated at a specialist tropical medicine center in the United Kingdom.
Methods:
The electronic patient records of 17 patients less than 18 years old with CL who were treated at University College London Hospitals between October 2015 and June 2025 were accessed to gather data including demographics (age, sex, country of origin), likely country of CL acquisition, causative species of Leishmania , treatment given and treatment outcome. Causative agents included L. donovani complex (n = 6), L. major (n = 5), L. tropica (n = 4), L. Viannia subgenus (n = 1) and a Leishmania species where subgenus or species could not be determined (n = 1).
Results:
Conservative management (2/17), oral miltefosine (9/17), intralesional meglumine antimoniate (3/17) and intravenous liposomal amphotericin B (LAMB; 3/17) were used as first-line treatment approaches in this cohort. Two patients were lost to follow-up, but complete resolution was observed in 14 of the remaining 15 patients by day 180 post-treatment initiation, with 1 child's lesion taking longer than this to fully re-epithelialize. Adverse effects of treatment were observed in 6/17 (35%) patients and were mild or moderate.
Conclusions:
Our data show that miltefosine, intralesional meglumine antimoniate and LAMB are effective, safe and well-tolerated treatments for children with CL in non-endemic settings. Management of children and young adults with CL may present additional complexity compared to adults, such as difficulty obtaining biopsy samples, lack of evidence for drug dosing regimens and tolerability of painful injections, which need to be administered repeatedly. Individualized treatment decisions should be made in conjunction with children, young people and their families, and a multidisciplinary approach is recommended.
Related Concept Videos
01:30Leishmaniasis
01:21Antiprotozoal Agents